BGI Genomics Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Lijian Zhao
Chief executive officer
CN¥1.4m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 3.9yrs |
| CEO ownership | 0.06% |
| Management average tenure | no data |
| Board average tenure | 2.9yrs |
Recent management updates
Recent updates
BGI Genomics Co., Ltd. (SZSE:300676) Held Back By Insufficient Growth Even After Shares Climb 26%
Feb 07
Does BGI Genomics (SZSE:300676) Have A Healthy Balance Sheet?
Jan 21Is BGI Genomics (SZSE:300676) Using Too Much Debt?
Oct 22BGI Genomics Co., Ltd. (SZSE:300676) Held Back By Insufficient Growth Even After Shares Climb 31%
Oct 01Is BGI Genomics (SZSE:300676) A Risky Investment?
Jul 15Why Investors Shouldn't Be Surprised By BGI Genomics Co., Ltd.'s (SZSE:300676) Low P/S
May 22BGI Genomics' (SZSE:300676) Conservative Accounting Might Explain Soft Earnings
Apr 21Here's Why BGI Genomics (SZSE:300676) Can Manage Its Debt Responsibly
Mar 25CEO
Lijian Zhao (48 yo)
3.9yrs
Tenure
CN¥1,361,400
Compensation
Mr. Lijian Zhao serves as a Director of BGI Genomics Co., Ltd., since June 17, 2021 and serves its General Manager.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 3.9yrs | CN¥1.36m | 0.064% CN¥ 11.7m | |
| CFO, Deputy GM & Non Independent Director | less than a year | CN¥917.50k | 0.013% CN¥ 2.4m | |
| Deputy GM & Director | 1.7yrs | CN¥1.07m | 0.032% CN¥ 5.9m | |
| Deputy GM & Non Independent Director | less than a year | CN¥1.10m | no data | |
| Member of Scientific Advisory Board | 8.2yrs | no data | no data | |
| Chairman | 9.9yrs | no data | 0.67% CN¥ 122.1m | |
| Member of Supervisory Board | 9.9yrs | no data | 0.00092% CN¥ 168.8k | |
| Independent Director | 3.9yrs | CN¥252.00k | no data | |
| Chairman of the Supervisory Board | 3.9yrs | no data | no data | |
| Independent Director | 1.8yrs | CN¥108.80k | no data | |
| Non Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data |
2.9yrs
Average Tenure
48.5yo
Average Age
Experienced Board: 300676's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/12 08:27 |
| End of Day Share Price | 2025/05/12 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BGI Genomics Co., Ltd. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yiling Chen | Guosen Securities Co., Ltd. |
| Hanqing Zhu | Guosen Securities Co., Ltd. |
| Wen Dai | Huatai Research |